Access to Patient Information Sample Clauses

Access to Patient Information. In the course of performing its duties under this Agreement, Contractor will have access to or knowledge of health records or other personal and confidential information regarding patients. Contractor will safeguard and serve as the custodian of health records and other personal and confidential information to ensure that the information is not improperly disclosed and to comply with the regulations promulgated by the United States Department of Health and Human Services, pursuant to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as the same may be amended from time to time (collectively the “HIPAA Regulations”), the Health Information Technology for Economic and Clinical Health (HITECH) Act, and other federal and state regulations governing the confidentiality of health information.
AutoNDA by SimpleDocs
Access to Patient Information. Employer agrees to permit the Practitioner, at any time upon request, to gain full access to records, computer entries, patient or insurance payment information, EOB’s, and any other information or details submitted by the patient that is needed to verify medical records or the accuracy of billing information for auditing purposes.
Access to Patient Information. Employer agrees to permit the Practitioner, at any time upon request, to gain full access to records, computer entries, patient or insurance payment information, EOB’s, and any other information or details submitted by the patient that is needed to verify medical records or the accuracy of billing information for auditing purposes. Equipment & Supplies. Employer, at their own expense, shall provide all necessary equipment, materials, and supplies that will allow the Practitioner to serve their patients in accordance with the current and most advanced procedures as economically possible. Digital Records. Employer, at their own expense, shall be responsible for recording and maintaining, along with any digital backups, all health and medical records of the patients. This shall include, but not be limited to, health history, X-rays, treatments, diagnosis, and any other details that should be kept on behalf of the patient.
Access to Patient Information. SULZBACHER shall allow Clinician to access and utilize patient information including electronic medical records of their patients for the purpose of treatment or certain health care operations to the extent permitted by the Memorandum of Understanding in place between the agencies for the purpose of promoting collaboration to provide health services to children and youth.
Access to Patient Information. Recognizing that the Selling Entities may need to maintain some or all of the patient information included in the Historical Information, the parties agree that the Selling Entities may retain some or all of such patient information as mutually agreed upon by Buyer and Seller; provided, however, that the Selling Entities shall maintain such patient information that is not transferred to Buyer for a period of at least seven (7) years following the Closing and, during such period, shall, as permitted by Law, provide Buyer and its representatives full access, for reasonable purposes, during normal business hours to such patient information.

Related to Access to Patient Information

  • Client Information (2) Protected Health Information in any form including without limitation, Electronic Protected Health Information or Unsecured Protected Health Information (herein “PHI”);

  • Access to Data Operator shall make Data in the possession of the Operator available to the LEA within five (5) business days of a request by the LEA.

  • Access to Information Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!